CBD Oil for Sleep and Interstitial Lung Disease (IPF/ILD): Nocturnal Hypoxemia, Non-Productive Cough Hyperreactivity, Dyspnea Anxiety, and the Pirfenidone/Nintedanib Antifibrotic Interaction | PureCraft CBD

CBD Oil and ILD Medications: Pirfenidone, Nintedanib, Prednisone (CTD-ILD/HP/Sarcoid), and Supplemental Oxygen

Pirfenidone (Esbriet — FDA-approved antifibrotic for IPF) — CYP1A2 primary metabolism, CYP2C9 and CYP2D6 secondary: the most important IPF-specific interaction: Pirfenidone is primarily metabolized by CYP1A2 (approximately seventy to eighty percent of the metabolic pathway) with minor contributions from CYP2C9 and CYP2D6. CBD's CYP inhibition profile is primarily CYP3A4 (strongest), CYP2C9, and CYP2D6, with relatively weaker inhibition of CYP1A2 compared to the more potent CYP1A2 inhibitors (fluvoxamine, ciprofloxacin). The secondary CYP2C9 and CYP2D6 inhibition by CBD could modestly increase pirfenidone plasma levels through the minor metabolic pathways, though the primary CYP1A2 pathway being less strongly inhibited by CBD at supplemental doses limits the magnitude of this interaction. Pirfenidone's side effect profile — GI upset (nausea, dyspepsia), photosensitivity, and rarely elevated liver enzymes — is potentially worsened by higher plasma levels. The clinical significance of the CBD-pirfenidone interaction at supplemental CBD doses is uncertain and likely modest, but physician disclosure before starting CBD is appropriate so that pirfenidone tolerance and LFTs can be monitored. Importantly, pirfenidone levels can also be significantly affected by dietary factors: grapefruit and smoking both affect CYP1A2 significantly (smoking induces CYP1A2, increasing pirfenidone clearance; stopping smoking during IPF management can unexpectedly raise pirfenidone levels). The CBD interaction is mechanistically similar to grapefruit at the CYP level — a modest CYP-mediated increase in pirfenidone exposure — and should be handled with similar clinical monitoring awareness.

Nintedanib (Ofev — FDA-approved antifibrotic for IPF and SSc-ILD; also approved for ILD after systemic progression of ILD in various CTDs) — P-glycoprotein (P-gp) substrate and minor CYP3A4: same interaction context as the SSc post: As covered in the scleroderma post, nintedanib is primarily a P-gp substrate with minor CYP3A4 metabolism. CBD's CYP3A4 inhibition could modestly increase nintedanib levels. The mechanistic complementarity of nintedanib (PDGFR/VEGFR/FGFR multi-kinase inhibitor targeting fibroblast activation) and CB2/TGF-β1 (endocannabinoid anti-fibrotic targeting the TGF-β1 signaling axis) is the same as noted in the SSc post: nintedanib addresses fibroblast proliferation and differentiation (downstream of TGF-β1), while CBD/CB2 addresses TGF-β1 production and signaling upstream. The GI side effects of nintedanib (diarrhea in fifty to sixty percent of patients) do not produce a direct sleep disruption mechanism comparable to SSc esophageal disease, but may reduce overall absorption of oral CBD capsules/gummies if GI motility is severely accelerated — another reason the sublingual oil delivery (bypassing GI transit entirely) is particularly valuable for IPF patients on nintedanib.

Prednisone (used in CTD-ILD, hypersensitivity pneumonitis, sarcoidosis, and some non-IPF ILD subtypes — NOT routinely used in IPF, where corticosteroids are generally not beneficial and may worsen outcomes) — same CYP3A4/AANAT corticosteroid insomnia mechanisms as prior posts: IPF is treated with antifibrotics (pirfenidone or nintedanib), not corticosteroids. However, other ILD subtypes — hypersensitivity pneumonitis (HP), sarcoidosis ILD, CTD-ILD, and acute exacerbations of non-IPF ILD — are frequently treated with prednisone, and the same corticosteroid insomnia mechanisms (AANAT-mediated melatonin suppression, GR arousal activation) described throughout this series apply in those contexts. For the rare patient with IPF who receives a short course of prednisone for acute exacerbation, the same high-dose corticosteroid insomnia protocol applies. The distinction is important: the pirfenidone/nintedanib-treated IPF patient does not have corticosteroid insomnia as a primary sleep mechanism, while the sarcoidosis-ILD or HP patient on prednisone does.

Supplemental oxygen (LTOT — long-term oxygen therapy, prescribed when resting SpO2 ≤88% or exertional desaturation below 88%) — no pharmacological interaction with CBD: Supplemental oxygen — administered by nasal cannula or face mask during sleep — is prescribed for ILD patients with significant hypoxemia to maintain SpO2 above ninety percent during sleep. There is no pharmacological interaction between supplemental oxygen and CBD. However, the equipment and experience of supplemental oxygen itself can disrupt sleep through mechanical discomfort (nasal cannula skin irritation, tubing noise, equipment sounds), and the act of needing supplemental oxygen overnight is psychologically significant — a concrete nightly reminder of the severity of the lung disease. The TRPV1 desensitization mechanism that CBD provides for the supine-position cough and dyspnea is fully compatible with supplemental oxygen use; the mechanisms are additive rather than competing.

IPF Mild-Moderate on Antifibrotic Therapy: The Cough, Dyspnea Anxiety, and Prognosis Anxiety Protocol

For people with mild-to-moderate IPF (FVC above seventy percent, no supplemental oxygen at rest) on pirfenidone or nintedanib — who experience significant nocturnal cough disruption, pre-sleep dyspnea anticipatory anxiety, and the progressive IPF prognosis anxiety that intensifies at night — the CBD protocol addresses all four channels from day one of use. The Nano CBD Broad Spectrum Oil taken sixty to ninety minutes before sleep is the highest-priority IPF product for two converging reasons: sublingual delivery bypasses GI absorption entirely (the nintedanib-associated diarrhea that affects fifty to sixty percent of IPF patients on nintedanib can impair GI absorption of capsules and gummies, making sublingual delivery not just preferable but clinically important), and the TRPV1 desensitization mechanism begins thirty to sixty minutes after sublingual absorption — reaching pulmonary C-fiber peak effect at approximately the time the patient lies down to sleep, providing the maximum TRPV1 cough suppression effect during the critical supine-position cough-triggering period at sleep onset. The 5-HT1A mechanism in the oil simultaneously addresses both the suffocation-fear hyperarousal of the pre-sleep dyspnea anticipatory anxiety and the existential terminal-prognosis rumination that characterizes IPF pre-sleep cognition. The CBD+CBN+D9+Melatonin Gummies sixty minutes before sleep provide CBN's N3 sleep architecture restoration — IPF patients frequently experience severely fragmented sleep architecture from years of cough-awakening, hypoxemic arousal, and nocturnal dyspnea, and the N3 deficit is profound — while melatonin supports the circadian sleep onset transition. The Nano CBD Water-Soluble Broad Spectrum Softgels at sleep onset extend TRPV1 and CB2 coverage through the overnight period, maintaining cough suppression coverage through the second half of the night. The Nano CBD Broad Spectrum Gummies for daytime maintenance provide the consistent CB2/TGF-β1 anti-fibrotic tonic throughout the day, supporting the mechanism complementary to pirfenidone or nintedanib antifibrotic therapy. Pirfenidone disclosure to the pulmonologist before starting CBD is the most important safety step for IPF patients on pirfenidone specifically.

Advanced IPF with Supplemental Oxygen: The Palliative Comfort Sleep Protocol

For people with advanced IPF (FVC below fifty percent, supplemental oxygen required at rest or sleep) — who experience severe nocturnal hypoxemia despite LTOT, intense resting dyspnea and cough, suffocation-fear hyperarousal, and the end-stage prognosis anxiety of advancing IPF — the CBD protocol shifts toward palliative-comfort-focused support alongside optimized LTOT and specialist pulmonary care. At this stage, the CB2/TGF-β1 anti-fibrotic mechanism is less disease-modifying (the fibrosis is established and extensive) but remains relevant for its anti-inflammatory reduction of the macrophage-driven fibrotic inflammation that continues to progress; the TRPV1 and 5-HT1A mechanisms become the primary comfort-focused mechanisms. The Nano CBD Broad Spectrum Oil remains the highest-priority product in advanced IPF specifically because its TRPV1 desensitization of pulmonary C-fibers provides the most immediately perceptible symptom relief — reduction in the paroxysmal cough that disrupts sleep onset and produces nocturnal awakenings — and because its 5-HT1A mechanism addresses the suffocation-fear and existential anxiety that dominate the psychological experience of advanced IPF. The sublingual delivery is particularly important at this stage: advanced IPF patients often have reduced activity tolerance and may prefer the simplicity and rapid onset of sublingual oil over the effort of swallowing multiple capsules or gummies when severely dyspneic. The CBD+CBN+D9+Melatonin Gummies provide the melatonin and N3 restoration that helps any available sleep be as restorative as possible — the quality of the sleep that the LTOT-supplemented, CBD-supported ILD patient can achieve matters enormously for their daytime functional capacity, mood, and quality of life. Physician coordination for advanced IPF CBD use is important: palliative care involvement is typically appropriate at this stage, and the palliative care team is well-positioned to integrate CBD sleep support into the overall comfort-focused care plan alongside LTOT optimization, opioid-based dyspnea management if indicated, and psychosocial support. For advanced IPF patients awaiting lung transplant evaluation, the transplant program's supplement policies should be reviewed — some transplant programs have policies about supplement use during evaluation, and transparency with the transplant team about CBD use is important.

The ILD Sleep Protocol: Positional Optimization, Nocturnal SpO2 Monitoring, and FVC/PSQI Dual Tracking

Positional optimization for ILD sleep — the anti-supine strategy: The most effective non-pharmacological sleep intervention for ILD is positional: avoiding full supine position (which maximally reduces FRC and maximally worsens V/Q mismatch) in favor of a thirty-to-forty-five-degree semi-recumbent position using a wedge pillow or adjustable bed. The semi-recumbent position maintains a higher FRC, reduces the basilar-predominant V/Q mismatch of IPF (which is worst when posterior-dependent lung is maximally perfused in the flat supine position), and reduces the nasal/pharyngeal drainage that triggers supine-position cough. For patients who prefer lateral positioning, the right lateral decubitus position places the more-perfused right lung (which has higher blood flow at baseline from being larger) in the dependent position, which can worsen V/Q mismatch in bilateral-predominant IPF; left lateral decubitus may be slightly preferable. The semi-recumbent position, combined with the pre-sleep sublingual oil TRPV1 cough suppression, represents the most effective environmental-plus-pharmacological combination for IPF cough-onset sleep disruption.

Nocturnal pulse oximetry monitoring and CBD protocol adjustment: For ILD patients on supplemental oxygen, a wrist pulse oximeter (with overnight SpO2 logging capability) provides objective feedback on the nocturnal hypoxemia that the CBD protocol is helping manage. If overnight SpO2 logging shows consistent desaturation below eighty-eight percent despite LTOT, this is a medical issue requiring LTOT flow rate adjustment by the pulmonologist — not a CBD-addressable problem. If overnight logging shows fragmented SpO2 with multiple brief desaturation events followed by arousal-recovery, the CBD protocol's TRPV1 cough and CB2 anti-inflammatory mechanisms may reduce the frequency of cough-triggered desaturation events over weeks; comparing pre- and post-CBD overnight SpO2 profiles provides an objective measure of the CBD protocol's respiratory impact beyond the subjective PSQI sleep quality score.

FVC (forced vital capacity) trajectory and PSQI dual tracking: The standard IPF disease activity monitoring includes FVC percent predicted — a decline of ten percent or more in FVC over twelve months is the clinical threshold for meaningful progression and is used to assess antifibrotic therapy efficacy. Tracking PSQI sleep quality score alongside FVC provides the two-variable framework for assessing the CBD protocol in IPF: if PSQI improves while FVC is declining at the same rate, the CBD protocol is providing sleep-quality benefit independent of (and despite) progressive fibrosis; if PSQI improves at a rate faster than FVC decline would predict, the CB2/TGF-β1 mechanism may be providing additive anti-fibrotic benefit to the antifibrotic therapy. Cough severity (using the validated Leicester Cough Questionnaire) alongside FVC and PSQI provides the three-variable assessment framework for the IPF CBD protocol response.

Can CBD oil help with my IPF cough that keeps me awake when I lie down?

IPF cough is one of the conditions where CBD oil's TRPV1 desensitization mechanism has the most mechanistically direct relevance in this series, and the honest answer is nuanced between what CBD can and cannot do for it. The IPF cough arises from TRPV1 hypersensitization on pulmonary C-fibers — the inflammatory and fibrotic milieu of the IPF lung lowers the activation threshold of these airway and alveolar sensory nerves to the point where normal breathing triggers the cough reflex, particularly in the supine position where vagal tone increases, airway caliber decreases, and nasal drainage contacts hypersensitized pharyngeal C-fibers. CBD's TRPV1 desensitization mechanism — through which CBD activates TRPV1 channels briefly and then causes prolonged receptor desensitization (tachyphylaxis) — specifically targets the sensitized, low-threshold TRPV1 channels that are generating the pathological cough reflex, reducing their excitability toward the normal physiological range. This is not the same as a cough suppressant (like dextromethorphan) that acts centrally to suppress the cough reflex at the brainstem level — CBD acts peripherally at the C-fiber sensory terminals to reduce the afferent signal that triggers the cough reflex in the first place. The clinical evidence for CBD's cough reduction in IPF specifically is preclinical and mechanistic rather than from large randomized trials, but the TRPV1 desensitization mechanism is well-established and directly applicable to the IPF cough pathophysiology. For the timing: the oil should be taken sixty to ninety minutes before lying down, so the TRPV1 desensitization has peaked before the moment of supine positioning — the most common mistake is taking the oil while already lying down and experiencing coughing, when the TRPV1 desensitization onset (twenty to thirty minutes after sublingual absorption, full effect at sixty to ninety minutes) means the benefit arrives after the worst of the cough episode has already disrupted sleep onset. Preemptive TRPV1 desensitization before lying down is the key timing principle for IPF cough. The oil will not cure or eliminate IPF cough — IPF cough is driven by the underlying fibrotic disease, and as long as the fibrosis persists, the TRPV1 sensitization will persist — but it can meaningfully reduce the severity and frequency of the supine-position nocturnal cough that prevents sleep onset and causes nocturnal awakenings, allowing the exhausted IPF patient to fall asleep and stay asleep through the critical first sleep cycles.

Is CBD oil safe with pirfenidone for IPF, and do I need to tell my pulmonologist?

Yes, telling your pulmonologist before starting CBD while on pirfenidone is the most important safety step, and this is not a formulaic answer — there is a specific pharmacological reason why the pirfenidone context requires pulmonologist disclosure more urgently than many other conditions in this series. Pirfenidone is primarily metabolized by CYP1A2 (approximately seventy to eighty percent of the metabolic pathway). CBD inhibits multiple CYP enzymes, with its strongest inhibition at CYP3A4 and meaningful inhibition at CYP2C9 and CYP2D6. CBD's inhibition of CYP1A2 — the primary pirfenidone-metabolizing enzyme — is less potent than its CYP3A4 inhibition, but the minor metabolic pathways of pirfenidone (CYP2C9 and CYP2D6) are both inhibited by CBD, and the combined effect across CYP2C9, CYP2D6, and partial CYP1A2 inhibition could modestly increase pirfenidone plasma exposure. The clinical significance at supplemental CBD doses is uncertain — likely modest — but pirfenidone at higher-than-expected plasma levels increases the risk of its known side effects: GI intolerance (nausea, dyspepsia), photosensitivity rash, and elevated liver function tests. Your pulmonologist can monitor pirfenidone tolerance and LFTs more closely during the first four to eight weeks of concurrent CBD use, which is the appropriate clinical response to a modest and uncertain CYP interaction. The pirfenidone-CBD disclosure also matters because your pulmonologist needs complete information to interpret any side effects or lab abnormalities that arise during concurrent use: if LFTs elevate during CBD + pirfenidone use, the pulmonologist needs to know about both agents to correctly attribute the finding. For the complementary question — does CBD add any benefit alongside pirfenidone? — the CB2/TGF-β1 anti-fibrotic mechanism is mechanistically complementary to pirfenidone's TGF-β1 and PDGF signaling inhibition: pirfenidone inhibits TGF-β1 signaling through a separate pathway (reducing TGF-β1-stimulated collagen gene expression at the Smad level) while CB2 inhibits TGF-β1 signaling through the endocannabinoid/CB2 pathway. These are non-overlapping mechanisms acting on the same fibrotic endpoint, making them complementary rather than redundant — though the clinical evidence for CB2 anti-fibrotic effects in human IPF is preclinical and should be framed accordingly as a mechanistically rational add-on rather than a proven therapy.

I'm terrified every time I lie down to sleep because of the breathlessness — how does CBD oil help with the fear of suffocation?

The fear of suffocation that breathlessness from IPF produces at night is the most physiologically primal anxiety that appears in this series, and understanding the distinction between CBD's effect on the fear versus the breathlessness itself helps set accurate expectations. The breathlessness of IPF arises from the fibrotic restriction of the lung — the actual physical inability to exchange enough gas — and from the hypersensitized pulmonary C-fiber TRPV1 afferents that amplify the perceived breathlessness beyond what the gas exchange deficit alone would produce. CBD addresses both: the CB2/TGF-β1 mechanism addresses the fibrosis (slowly, over weeks-months); the TRPV1 desensitization addresses the C-fiber hypersensitivity that amplifies the perceived breathlessness signal (more rapidly, within sixty to ninety minutes of the sublingual dose). The fear of the breathlessness — the suffocation-terror that IPF patients describe when lying down at night — is a separate, layered phenomenon. The experienced breathlessness activates the brainstem survival circuits for air hunger, which generates a fear response that is sub-cortical and bypasses rational processing — this is not irrational anxiety, it is the nervous system's correct identification of a real physiological threat and the activation of the survival response appropriate to that threat. CBD's 5-HT1A partial agonism reduces the amygdala-mediated amplification of this survival fear — the physiological component of the terror that produces the racing heart, the sympathetic surge, the inability to lie down because the body is screaming "danger" before the breathing even worsens. The 5-HT1A mechanism does not eliminate the appropriate respiratory awareness — the patient still perceives the breathlessness and still takes appropriate action if it worsens — but it attenuates the panic-state physiological response to the breathlessness, reducing the suffocation-terror from a consuming, paralyzing fear to a manageable awareness. Practically: patients who have this experience often describe the fear of lying down as almost worse than the lying down itself — the anticipatory terror of the pre-sleep period being the primary sleep-onset barrier. CBD's 5-HT1A mechanism works most effectively for this anticipatory pre-sleep suffocation-fear, reducing the amygdala's physiological amplification of the fear memory in the hour before sleep onset. The combined effect of TRPV1 cough-and-perceived-dyspnea reduction (less breathlessness signal) plus 5-HT1A suffocation-fear attenuation (less fear response to the remaining signal) provides a two-mechanism approach to the lying-down-terror that no single mechanism alone addresses as completely.

How is CBD oil for IPF sleep different from CBD oil for scleroderma ILD?

Both IPF and SSc-ILD involve pulmonary fibrosis and share the CB2/TGF-β1/PPARγ anti-fibrotic mechanism as a relevant CBD pathway, but the ILD post and the SSc post differ in important ways that make each distinct in the sleep cluster. In SSc-ILD (covered in the scleroderma post), the ILD is one of four concurrent sleep disruption mechanisms: the primary nocturnal disruptors in SSc are Raynaud's vasospasm (the dominant sleep mechanism, producing cold-triggered nocturnal digital vasospasm) and esophageal GERD (from fibrotic LES incompetence, producing nocturnal reflux), with ILD as a significant but not always primary sleep disruptor except in dSSc with extensive ILD. SSc-ILD is typically an NSIP pattern (more cellular, more potentially responsive to immunosuppression) rather than IPF's UIP pattern (more established fibrosis, less responsive to immunosuppression). In IPF (this post), the ILD is the entire disease — there is no concurrent Raynaud's, no GERD, no skin tightening — and the ILD mechanisms operate in isolation as the complete sleep disruption picture. This changes the CBD protocol priorities significantly: the IPF post has no Raynaud's temperature management protocol, no esophageal elevation strategy, no CTD-specific drug interactions (bosentan for SSc-PAH, mycophenolate for SSc-ILD). The IPF protocol is the most pulmonary-focused protocol in the series, with TRPV1 for cough and perceived dyspnea taking the lead role that Raynaud's temperature management and GI positioning take in SSc. The drug interaction picture is also entirely different: pirfenidone CYP1A2/2C9/2D6 is the primary IPF-specific interaction (no equivalent in SSc); bosentan CYP2C9+3A4 is the most important SSc interaction (irrelevant to IPF). The psychological burden is also distinct: SSc has Raynaud's-driven anxiety, the body-image impact of skin tightening, and the esophageal discomfort anxiety; IPF has the pure pulmonary trajectory anxiety — a progressive, inexorable decline in lung function with no disease reversal option and a two-to-five-year median survival, a prognosis burden that is more severe in prognostic certainty than SSc's variable course. The suffocation-fear hyperarousal is more intense in IPF than in SSc because IPF dyspnea is more severe as a resting and nocturnal symptom — SSc-ILD typically produces exertional dyspnea before resting dyspnea, while IPF frequently produces resting and nocturnal dyspnea at a severity that generates the suffocation-fear at bedtime.

How long will CBD oil take to help with IPF sleep, and what should I notice changing first?

The temporal sequence of CBD protocol response in IPF is shaped by the different onset speeds of the four mechanisms, and the first perceptible change for most IPF patients is the TRPV1 cough response — the fastest-onset mechanism in the series for this application. On the first night of using the sublingual oil sixty to ninety minutes before lying down, the pre-established TRPV1 desensitization typically produces a noticeable reduction in the severity or delay of the supine-position cough onset — patients often describe their first night with the oil as: "I usually start coughing immediately when I lie down; tonight I was able to lie down for twenty minutes before the coughing started." This window-extension effect — not cough elimination, but delay and severity reduction — is typically the first perceptible change because it operates through the most rapid of the four mechanisms (TRPV1 desensitization, onset twenty to sixty minutes) and because the supine-position cough is the most time-specific, position-triggered ILD symptom that CBD directly targets. Over the first one to two weeks, the 5-HT1A anxiolytic effect on the pre-sleep suffocation-fear and lying-down terror typically becomes noticeable — not as the disappearance of the breathlessness, but as a reduction in the physiological intensity of the panic component of the pre-sleep anxiety about lying down. The experience changes from "I am terrified to lie down because I know I will suffocate" to "I am concerned about lying down, but I can manage the concern" — a distinction that is subtle in description but profound in the actual experience of the pre-sleep period. Over four to eight weeks, the CBN N3 sleep architecture restoration produces the cumulative improvement in sleep quality that the fragmented, cough-disrupted IPF sleep architecture requires — the progressive rebuilding of restorative slow-wave sleep that transforms the physically exhausted but non-rested IPF sleep pattern toward genuinely restorative sleep. The CB2/TGF-β1 anti-fibrotic benefit operates on the IPF disease trajectory timescale — months to years of consistent exposure — and cannot be measured by sleep quality alone; FVC trajectory alongside PSQI is the appropriate dual tracking. The FVC change from CBD alone in IPF is unlikely to be dramatic and should be assessed only as an adjunctive benefit alongside antifibrotic therapy, not as a primary expectation.

I have sarcoidosis with lung involvement, not IPF — how does CBD oil apply to my situation?

Sarcoidosis ILD has a distinct pathological mechanism from IPF — sarcoidosis produces non-caseating granulomata (organized collections of activated macrophages and epithelioid cells, surrounded by lymphocytes) throughout the lungs (and potentially any organ), while IPF is a disease of fibroblast activation and collagen deposition without granulomatous inflammation. The sleep disruption in pulmonary sarcoidosis has some overlap with IPF (restrictive ILD physiology, cough, dyspnea) but also important unique features. Sarcoidosis-specific fatigue — reported as the most disabling symptom by many sarcoidosis patients and distinct from the purely mechanical dyspnea fatigue of IPF — involves multiple mechanisms: the inflammatory cytokine burden from active granulomata (TNF-α is particularly elevated in active sarcoidosis, and the TNF-α driven fatigue mechanism resembles the ME/CFS cytokine-fatigue parallel); small fiber neuropathy from sarcoid neuropathic involvement (neurosarcoidosis); and, in severe sarcoidosis with extensive lung involvement, the sleep architecture disruption from ILD-driven nocturnal hypoxemia. CBD's CB2/NF-κB mechanism at macrophages — which are the dominant cellular effectors of sarcoid granuloma formation and maintenance — is directly relevant to sarcoidosis ILD: macrophage TNF-α and IL-12 production drives the granulomatous inflammation, and CB2 activation suppresses the macrophage NF-κB-driven cytokine cascade that sustains the granulomata. The TRPV1 desensitization for sarcoid ILD cough and dyspnea operates through the same mechanism as IPF, as the TRPV1 sensitization by the sarcoid inflammatory milieu produces the same cough hypersensitivity. The sarcoidosis-specific caveat is hypercalcemia: sarcoid granuloma macrophages produce the enzyme CYP27B1 that converts 25-OH vitamin D to 1,25-OH vitamin D, causing hypercalcemia in approximately ten percent of sarcoidosis patients. Vitamin D supplementation is contraindicated or requires careful monitoring in sarcoidosis with hypercalcemia. CBD itself has no interaction with calcium or vitamin D metabolism, but the physician managing sarcoidosis should be aware of all supplements in the context of monitoring for sarcoid hypercalcemia. The prednisone used in active sarcoidosis triggers the same corticosteroid insomnia mechanisms as all other posts; the FAAH/HPA counterbalance and melatonin replacement from the CBN/Melatonin Gummies are fully applicable to sarcoidosis patients on prednisone-based therapy.

Medical Disclaimer

This article is for informational and educational purposes only. It is not intended to diagnose, treat, cure, or prevent any disease or medical condition, including idiopathic pulmonary fibrosis, interstitial lung disease, or any sleep disorder. CBD oil is not a substitute for physician-directed IPF treatment with pirfenidone or nintedanib, supplemental oxygen therapy, or pulmonary specialist care. Patients on pirfenidone must disclose CBD use to their pulmonologist before starting, given the CYP interaction considerations. Advanced IPF management including CBD supplementation should be coordinated with the treating pulmonologist and, where appropriate, palliative care specialist. CBD oil is not a proven anti-fibrotic therapy in human clinical trials. The statements in this article have not been evaluated by the Food and Drug Administration. CBD products are not intended to diagnose, treat, cure, or prevent any disease. Individual responses to CBD vary significantly.